Celltrion gets EMA nod for subcutaneous infliximab biosimilar 28-Nov-2019 By Vassia Barba Celltrion receives EMA marketing authorisation for Remsima SC, the first subcutaneously-administered option for delivery of infliximab, a treatment for rheumatoid arthritis.
Teva launches biosimilar rival to Roche's Rituxan with 10% discount 19-Nov-2019 By Nick Taylor Teva and Celltrion Healthcare launch the first biosimilar rival to Roche’s Rituxan in the US.
